A new medicine can prevent the disease and symptoms of COVID-19 to people exposed to coronovationas a new international clinical trial showed.
The results could be particularly important for families, whose members are at high risk of serious complications from the coronation. The drug Ensitrelvir is already approved in Japan to treat mild to moderate COVID cases.
The test has shown that it also has the ability to protect against the disease. Non-infected people who began to take the antiviral within 72 hours of the first occurrence of symptoms in a household member were significantly less likely to be infected with COVID-19 compared to placebo.
Among more than 2,000 US-in-Testing participants and other countries, 9% of placebo have developed confirmed COVID-19. This is compared to only 2.9% of people receiving Ensitrelvir, that is a 67% reduction in the risk of COVID-19 illness.
‘In addition to vaccination, the prophylaxis after the exposure by timely taking an antiviral drug Oral would be a valuable way to prevent COVID-19 illness to people who have been exposed, especially people with high risk of serious disease, “said a peer professor at the University of Virginia Medical School, Frederick Heiden, who has helped her to design the test. In San Francisco.
The clinical trial was conducted between June 2023 and September 2024 and was double blind, that is, neither the researchers nor the participants knew if they received Ensitrelvir or placebo. Among the participants in the test, t37% had at least one risk factor for the development of serious (and potentially life -threatening) complications. The risk of developing Covid has declined significantly, and there were no hospitalizations or deaths in either groups.
Researchers describe the pharmaceutical substance as effective and generally well tolerated for the prevention of COVID-19. Before the drug becomes available in the US, however, the Federal Food and Drug Administration (FDA) should approve it for this purpose.